Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
More Time For EU Nitrosamine Evaluations Due To COVID-19
Companies Are Allowed Additional Six Months
Mar 27 2020
•
By
Vibha Sharma
Sponsors Have More Time For Nitrosamine-Related Evaluations • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Manufacturing
More from Compliance